CSL Behring, a global leader in biotherapeutics with specialized expertise in rare diseases, selected BrightInsight as its digital health partner for our unified platform, which allows them to develop and host everything from digital health devices to apps, algorithms and Software as a Medical Device (SaMD) at scale–while maintaining compliance with global privacy, security, quality and regulatory requirements.
The first product to come to market since our partnership began is the Hizentra app, which was built for adult patients taking Hizentra for primary immune deficiency (PID) or for chronic inflammatory demyelinating polyneuropathy (CIDP).
Read the case study to learn more about the process of bringing the Hizentra app to market.
CIDP is a rare disease that affects roughly 30,000 Americans and causes progressive weakness and impaired sensory function in the arms and legs. It’s treated with Hizentra, a self-administered infusion treatment that requires close tracking of timing and location of infusion sites. Built on the BrightInsight Platform®, the Hizentra app enables better disease management, by allowing patients to track infusions, get treatment reminders, and record and share their infusion journal with their doctor.
Since the launch, over 3,000 users have downloaded and used the app–and this is just the beginning of what’s to come from the CSL Behring and BrightInsight partnership.
“BrightInsight’s Platform allows us to focus on therapeutic innovation, rather than the underlying digital technology,” says Brian Johnson, Senior Director of Customer Engagement Management at CSL Behring.
We’re excited to help enable this industry-leading innovation in the rare disease space and see how together, we can create more holistic treatment experiences for patients dealing with PID, CIDP and other diseases.